| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Ho William Tai-Wei | 5.6% | $614,820 | 4,098,800 | William Tai-Wei Ho | 31 Dec 2024 | |||
| BIOS Fund II, LP | 4% | -60% | $849,245 | -$18,941,314 | 391,357 | -96% | BIOS Capital Management, LP | 22 Dec 2025 |
| HIRSCHMAN ORIN | 4.4% | -46% | $23,983 | -$966,715 | 149,895 | -98% | Orin Hirschman | 30 Jun 2025 |
| Alyeska Investment Group, L.P. | 2.6% | -73% | $14,243 | -$1,144,329 | 89,021 | -99% | Alyeska Investment Group, L.P. | 30 Jun 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 286,664 shares of IN8BIO, INC. - Common Stock, par value $0.0001 per share (INAB). This represents 2.9% of the company’s total 9,783,925 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 286,664 | $622,061 | $2.17 | 1 | |
| 2025 Q2 | 286,664 | $599,128 | -$19,546,303 | $2.09 | 1 |
| 2025 Q1 | 21,678,562 | $3,599,041 | -$1,466,432 | $0.17 | 28 |
| 2024 Q4 | 30,029,181 | $7,723,566 | +$3,536,854 | $0.26 | 25 |
| 2024 Q3 | 7,625,615 | $2,058,934 | -$108,309 | $0.27 | 25 |
| 2024 Q2 | 7,101,123 | $6,010,532 | -$1,014,974 | $0.85 | 24 |
| 2024 Q1 | 8,640,434 | $10,226,862 | +$62,533 | $1.18 | 31 |
| 2023 Q4 | 8,582,106 | $11,395,569 | +$7,977,439 | $1.38 | 29 |
| 2023 Q3 | 2,476,816 | $2,575,547 | +$96,464 | $1.04 | 20 |
| 2023 Q2 | 2,329,087 | $3,585,975 | +$1,483,101 | $1.54 | 21 |
| 2023 Q1 | 1,366,256 | $1,775,782 | +$205,069 | $1.30 | 16 |
| 2022 Q4 | 1,208,609 | $2,791,095 | +$41,232 | $2.31 | 16 |
| 2022 Q3 | 1,177,755 | $2,376,000 | -$2,772,068 | $2.01 | 14 |
| 2022 Q2 | 2,328,724 | $5,439,000 | +$618,042 | $2.26 | 13 |
| 2022 Q1 | 2,049,195 | $7,019,000 | +$917,613 | $3.38 | 13 |
| 2021 Q4 | 1,777,567 | $7,803,000 | -$306,887 | $4.39 | 12 |
| 2021 Q3 | 1,772,956 | $12,192,000 | +$12,191,991 | $6.87 | 12 |